| Literature DB >> 35655802 |
Iwona Adamska1, Grzegorz Tokarczyk1.
Abstract
Parasol mushroom (Macrolepiota procera) is a fungus that is often included in the menu of people looking for replacements for meat products and at the same time appreciating mushrooms. Its fruiting bodies are known for their delicate flavor and aroma. The aim of the publication was to analyze the latest information (mainly from 2015 to 2021) on the chemical composition of the M. procera fruiting bodies and their antioxidant properties. The data on other health-promoting properties and the possibilities of using these mushrooms in medicine were also compiled and summarized, taking into account their antibacterial, antioxidant, anti-inflammatory, regulatory, antidepressant, and anticancer effects. Moreover, the influence of various forms of processing and conservation of raw mushroom on its health-promoting properties was discussed. The possibilities of controlling the quality of both the raw material and the prepared dishes were also discussed. Such an opportunity is offered by the possibility of modifying the growing conditions, in particular, the appropriate selection of the substrate for mushroom cultivation and the deliberate enrichment of its composition with the selected substances, which will then be incorporated into the fungus organism.Entities:
Year: 2022 PMID: 35655802 PMCID: PMC9153936 DOI: 10.1155/2022/5773275
Source DB: PubMed Journal: Int J Food Sci ISSN: 2314-5765
Figure 1The fruiting bodies of the fungus Macrolepiota procera. The appearance of the mushroom from above and below.
Production of cultivated mushrooms in the world in 2018-2020 (data according to FAOSTAT [17]).
| Country | Production volume (tons) | Participation in world production (%) | ||||
|---|---|---|---|---|---|---|
| 2018 | 2019 | 2020 | 2018 | 2019 | 2020 | |
| China | 37,890,000 | 38,950,652 | 40,000,000 | 93.32 | 93.33 | 93.5 |
| Japan | 467,000 | 470,000 | 471,810 | 1.15 | 1.27 | 1.10 |
| USA | 416,050 | 383,960 | 370,280 | 1.02 | 0.92 | 0.86 |
| Poland | 200,160 | 234,700 | 182,900 | 0.49 | 0.56 | 0.43 |
| Spain | 166,250 | 170,160 | 166,010 | 0.41 | 0.41 | 0.39 |
| Canada | 125,565 | 132,114 | 132,589 | 0.31 | 0.32 | 0.31 |
| United Kingdom | 98,509 | 101,339 | 105,660 | 0.24 | 0.24 | 0.25 |
| France | 82,980 | 87,560 | 80,010 | 0.20 | 0.21 | 0.19 |
| Germany | 73,230 | 71,790 | 78,730 | 0.18 | 0.17 | 0.18 |
| Italy | 70,670 | 70,860 | 69,210 | 0.17 | 0.17 | 0.16 |
| World | 40,600,043 | 41,736,063 | 42,792 893 | 100 | 100 | 100 |
Figure 2The percentage of the main nutrients in the fruiting bodies of Macrolepiota procera (in 100 g dw).
Figure 3Composition of the fruiting bodies depending on the method of preservation in comparison with the fresh fruiting bodies (developed in: Aydin et al. [41]).
The main components of the Macrolepiota procera.
| Group | Compound | Source of information about presence of component | Structure∗ | Molecular formula | Molecular weight (g/mol) | Color (and form) | Source of information about properties of component |
|---|---|---|---|---|---|---|---|
| Carbohydrates | Mannitol (hexitol) | [ |
| C6H14O6 | 182.17 | White crystalline powder | [ |
| Trehalose | [ |
| C12H22O11 | 342.30 | White crystalline powder | [ | |
| Glycerol (glycerin) | [ |
| C3H8O3 | 92.09 | Colorless syrupy liquid | [ | |
| Glucose | [ |
| C6H12O6 | 180.16 | Colorless crystals | [ | |
| Chitin | [ |
| (C8H13NO5)n | 203.19 | Powder, usually from yellow to beige | [ | |
|
| |||||||
| Amino acids | Alanine | [ |
| C3H7NO2 | 89.09 | White crystalline powder | [ |
| Proline | [ |
| C5H9NO2 | 115.13 | White crystals or crystalline powder | [ | |
| Glutamic acid | [ |
| C5H9NO4 | 147.13 | White crystalline powder | [ | |
| Serine | [ |
| C3H7NO3 | 105.09 | Solid | [ | |
| Fatty acids | Linoleic acid | [ |
| C18H32O2 | 280.45 | Colorless, oily liquid | [ |
| Oleic acid | [ |
| C18H34O2 | 282.46 | Colorless, oily liquid | [ | |
| Palmitic acid | [ |
| C16H32O2 | 256.42 | White crystalline scales or needles | [ | |
|
| |||||||
| Fenolic acids | Caffeic acid | [ |
| C9H8O4 | 180.16 | Light yellow crystalline powder or yellow crystals | [ |
| Cinnamic acid | [ |
| C9H8O2 | 148.17 | Colorless crystals | [ | |
| p-Coumaric acid | [ |
| C9H8O3 | 16416. | Light yellow to beige crystalline powder | [ | |
| Ferulic acid | [ |
| C10H10O4 | 194.18 | Light yellow powder | [ | |
| Gallic acid | [ |
| C7H6O5 | 170.12 | White solid or powder | [ | |
| Gentisic acid | [ |
| C7H6O4 | 154.12 | White to yellow powder | [ | |
| 4-Hydroxybenzoic acid (p-hydroxybenzoic acid) | [ |
| C7;H6O3 | 138.12 | White to light beige crystalline powder | [ | |
| Protocatechuic acid (3,4-dihydroxybenzoic acid) | [ |
| C7H6O4 | 154.12 | White to light brown crystalline powder | [ | |
| Syringic acid | [ |
| C9H10O5 | 198.17 | Light brown powder | [ | |
| Tannic acid | [ |
| C76H52O46 | 1701.19 | Light yellow to brown solid | [ | |
| Vanillic acid (4-hydroxy-3-methoxybenzoic acid) | [ |
| C8H8O4 | 168.15 | White to light yellow crystals or powder | [ | |
| Vitamins | Vitamin A (retinol) | [ |
| C20H30O | 286.50 | Oily liquid or yellow crystals | [ |
|
| [ |
| C29H50O2 | 430.71 | Light yellow oil | [ | |
| Ascorbic acid (vitamin C) | [ |
| C6H8O6 | 176.13 | White crystalline powder or colorless crystals | [ | |
|
| |||||||
| Fruit acids | Malic acid | [ |
| C4H6O5 | 134.09 | White crystalline powder | [ |
| Citric acid | [ |
| C6H8O7 | 192.12 | White (or colorless) crystalline solid | [ | |
|
| |||||||
| Carotenoids |
| [ |
| C40H56 | 536.87 | Red to brownish-red crystals or crystalline powder | [ |
| Lycopene | [ |
| C40H56 | 536.87 | Dark red solid | [ | |
|
| |||||||
| Indole and tryptophan derivatives | Indole | [ |
| C8H7N | 117.15 | White crystals | [ |
| L-Tryptophan | [ |
| C11H12N2O2 | 204.22 | Yellowish-white crystals or powder | [ | |
| 5-Hydroxytryptophan | [ |
| C11H12N2O3 | 220.22 | n.d. | [ | |
| 5-Methyltryptamine | [ |
| C11H14N2 | 174.24 | n.d. | [ | |
| Melatonin | [ |
| C13H16N2O2 | 232.28 | White-cream to yellowish crystalline powder | [ | |
| Tryptamine | [ |
| C10H12N2 | 160.22 | Slight-yellow or pale-white crystalline powder | [ | |
∗Structural formulas are derived from the source of information about the properties of the component.
Studies of antioxidant properties of substances present in the Macrolepiota procera fruiting bodies.
| Type of test∗ | Type of extracts∗ | Parameter determined | Results | Authors |
|---|---|---|---|---|
| (i) Total phenolic content | M | (i) Absorbance at 760 nm | (i) 36.25 ± 0.35 mg GAE/g extract | [ |
| (i) Reducing power | M | (i) n.d. (percentage of activity) | (i) 13.9 ± 0.6 mg GAE per g extract | [ |
| (i) Total phenolic content | M | (i) Absorbance at 760 nm | (i) TPC = 1.624 ± 0.026 mg GAE g−1 | [ |
| (i) DPPH | M | (i) Absorbance at 517 nm | (i) IC50 = 311.40 ± 1.28 | [ |
| (i) DPPH | M | (i) Absorbance at 515 nm (DPPH radical; percentage of activity; EC50) | (i) Activity: 65.41%; EC50 = 0.24 mg ml−1 | [ |
| (i) FRAP | M | (i) Absorbance at 595 nm | 1.8 mmol FE2+/100 g fw | [ |
| (i) Trolox equivalent antioxidative activity (TEAC) measurement | M, A | (i) Absorbance at 414 nm | (i) Cap—M: 8.92 ± 0.04; A: 36.08 ± 0.37; stalk—M: 5.09 ± 0.89; A: 21.83 ± 3.13 ( | [ |
| (i) DPPH | A | (i) Absorbance at 517 nm (IC50) | (i) RSA = 88.1 ± 2.1%; AAE = 191.00 ± 43.46 mg · l−1; IC50 = 0.948 mg | [ |
| (i) Total phenolic content | A | (i) Absorbance at 765 nm | (i) Sun-drying: 0.7658 ± 0.04366; freeze drying: 1.2329 ± 0.0556 (g% tannic acid) | [ |
| (i) Hydroxyl radical scavenging activity | AMd | (i) Absorbance at 535 nm (EC50) | (i) EC50 = 875 | [ |
∗Type of extracts: M: methanolic extract; A: aqueous extract; AMd: aqueous extract of fruit bodies M. dolichaula. ∗∗Type of test: DPPH: 1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity; FRAP: ferric reducing/antioxidant power assay; dw: dry weight; fw: fresh weight.
Figure 4The use of the Macrolepiota procera fruiting bodies for consumption.
Studies on the use of substances contained in Macrolepiota procera for medical purposes (from 2015 to 2021).
| Substances | Test organism | Type of test/parameter | Concentration/dose | Authors |
|---|---|---|---|---|
| Methanolic extract |
| Cytotoxic assay (absorbance at 570 nm), IC50 | 12.5 mg/ml, 25 mg/ml, 50 mg/ml, 100 mg/ml, 200 mg/ml | [ |
|
| Minimal inhibitory concentration (MIC) | 0.0195–40 mg/ml | ||
| Lepiotapro-cerins A-L |
| Nitric oxide production in RAW 264.7 macrophages (absorbance at 570 nm) | Dilutions up to the maximum concentration 25 | [ |
|
| Cytotoxicities against cancer cell lines (assess cell viability; absorbance at 595 nm), IC50 | |||
|
| Antimycobacterial assay (green fluorescent protein microplate assay) | n.d.∗ | ||
| Methanolic extract |
| Antimicrobial activity (diameter of the inhibition zones) | 150 mg/ml | [ |
| Aqueous extract |
| Microtitre plate method (inhibition of bacterial activity) | 50 mg/ml | [ |
| Methanolic extract |
| Agar well diffusion method | 100 mg/ml | [ |
| Methanolic extracts |
| Suppressive effect against tumor promoter-induced inflammation (by TPA) | n.d. | [ |
| Macrospin (trypsin inhibitors) |
| Protease inhibition assays | 0.11 | [ |
| Fructo-galactan PS II | (i) | (i) Content of NO (absorbance at 540 nm) | 12.5, 25, 50, 100, 200 | [ |
| Chloroform-acetone extract of Mk∗ | Bacteria: | Well diffusion method | 200 mg ml−1 | [ |
∗Symbols: n.d.: no date; Mk: Macrolepiota konradii.
Action mechanisms by bioactive substances contained in Macrolepiota procera, other than antioxidant (from 2015 to 2021).
| Activity | Result of mechanism | Mechanism | Authors |
|---|---|---|---|
| Antitumor effect | (i) Inhibition of the development of cancer cells (HeLa, A549, LS174) | (i) n.d.∗ | [ |
| (i) Inhibitory effect on the activity of tumor cells A-549, HL-60, MCF-7, SMMC-7721, SW-480 | (i) n.d. | [ | |
| Antibacterial effect | (i) Inhibition of activity of bacteria Bacillus cereus, B. subtilis and Proteus mirabilis and fungi Alternaria alternata, Aspergillus niger, Candida albicans, Fusarium oxysporum, Penicillium expansum, P. chrysogenum, and Trichoderma viride | (i) n.d. | [ |
| (i) Inhibition of colony development of | (i) n.d. | [ | |
| (ii) High anti-QS activity against | (i) n.d. | [ | |
| (i) Inhibition of the activity of | (i) n.d. | [ | |
| (ii) Inhibitory effect against | (ii) Inhibition of the growth of bacterial colonies (cell division) | [ | |
| (iii) Inhibition of the life activity of bacteria (Gram+: | (iii) Decrease in the viability of bacterial cells | [ | |
| Anti-inflammatory effect | (i) Inhibitory effect on induced inflammation | (i) Suppression of the TPA effect (swelling inhibition) | [ |
| (ii) Inhibition of inflammation | (ii) Inhibition of NO production in RAW 264.7 macrophages | [ | |
| Regulating effect | (i) Strong inhibition of trypsin and weaker of chymotrypsin | (i) n.d. | [ |
| Immunostimulating effect | (i) Activation of macrophages | (i) Increase in NO production | [ |
| Antidepressant effect | (i) Increase in serotonin and melatonin levels | (i) Presence of L-tryptophan, 5-hydroxytryptophan, tryptamine, serotonin, and melatonin—precursors and neurotransmitters with antidepressant properties | [ |
∗Symbols: n.d.: no data (not tested).
Figure 5Bioactive effect of Macrolepiota procera.